Login to Your Account

Firm to File BLA in 4Q

Dyax Angioedema Drug Meets Phase III Goal

By Donna Young

Tuesday, August 19, 2008
Dyax Corp.'s experimental drug DX-88 (ecallantide) met its goal of reducing symptoms of hereditary angioedema (HAE) in a second Phase III trial, sending shares of the firm up 15.5 percent Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription